

---

*This is a sample Patient Consent Form for medication assisted treatment with buprenorphine. Adapt any aspect of this policy to fit your clinic's needs and specific protocols for office-based treatment of opioid use disorder.*

## 1. Policy Statement:

Patients who agree to participate in the Medication Assisted Treatment (MAT) Program at this clinic must adhere to the policies and procedure of the program. Failure to adhere to the rules will result in dismissal from the program.

## 2. MAT Procedures

- Deciding if MAT with buprenorphine (suboxone) is right for you:
  - This practice will have a MAT team consisting of  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
[list providers, nurses, BHP, support staff]
  - The practice team will review the MAT program with the patient, including duration, expectations, pros and cons of medication, and the patient's motivations and goals.
  
- Preparation for Induction:
  - Patients will be given a physical exam, including lab tests.
  - Patients will have a MAT Overview Appointment. This visit will last approximately 30 minutes. The health care team will review lab results, as needed. The patient will review and sign the Treatment Agreement and Consent Form. Additional information covered during this appointment include safe storage, instructions for Induction Day 1 (including opioid stop times), communication plans, and follow-up visit schedule.
  - Patients and health care teams should discuss possible behavioral health care needs. If a need is identified at this stage, a referral will be requested or appointment scheduled for 1-4 weeks after Induction.
  - Patient may be asked to provide urine, hair, and blood sample or mouth swab at any time during the treatment process.
  
- Induction:
  - Patients may begin induction on the day of intake or the following business day
  - Induction lasts 1-3 days. Patients must come every day until the MAT provider determines induction is complete.

- Patients must abstain from taking any illicit drugs and notify the MAT provider or his/her staff of all drugs, herbals, and other medication they are taking.
- Maintenance:
  - Patients are expected to attend follow-up visits as agreed upon with health care team.
  - Patients follow-up will be scheduled to coincide with refills.
  - Patients will bring all buprenorphine/Suboxone pills/films with them to be counted at each appointment and each drug screening.
  - Patients are expected to participate in any referrals, if deemed necessary.
- Random Drug Screening:
  - Patients must appear within 24 hours of receiving call for a random screening.
  - Patients are expected to provide urine, hair, and blood sample or mouth swab.
  - Patients must inform the MAT provider or his/her staff of any relapse before it is found on drug screening.
  - If screening is positive, patients must be able to meet with the MAT provider at that time or when appointment is made.
- Medication:
  - It is illegal to give or sell your buprenorphine/Suboxone.
  - It is illegal to receive buprenorphine/Suboxone from more than one physician at a time.
  - There will be no early refills and no refill without an appointment.
  - You are expected to continue taking buprenorphine/Suboxone until your MAT provider instructs you to stop.

### 3. Reasons for Discontinuation of MAT with Buprenorphine (Suboxone)

- Failure to follow any rules or agreement.
- Cheating or attempting to cheat on drug screening.
- Selling or giving your medication.
- Discrepancies in medication count.
- Failure to provide payment or payment agreement for visits.
- Relapses – consuming illegal drugs or medication not approved by the MAT provider, including medication prescribed by another physician – will be discussed with the patient and health care team. Expectations and plans for handling relapses will be discussed prior to Induction (starting treatment).